Juric, Dejan

Abstract CT142: Prevalence of PIK3CA mutations in patients with hormone receptor-positive, human epidermal growth factor-2-negative advanced breast cancer from the SOLAR-1 trial

Rugo, H. S., Mayer, I., Conte, P., Loibl, S., Campone, M., Juric, D., Andre, F., Fritzemeier, M., He, W., Babbar, N., et al. (2019) · Cancer Research

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 17

Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours

Corcoran, R. B., Do, K. T., Cleary, J. M., Parikh, A. R., Yeku, O. O., Weekes, C. D., Veneris, J., Ahronian, L. G., Mauri, G., Van Seventer, E. E., et al. (2019) · Annals of Oncology

Melanoma and MAPK PathwaysCell death mechanisms and regulation

Cited by 17

LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients

Montero, A. J., Giordano, A., Jhaveri, K., Munster, P., Rodon, J., Lorusso, P., Orr, D., Bartolomé Arcilla, J., Italiano, A., Elias, A., et al. (2024) · Annals of Oncology

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 9